Pfizer (PFE) Wins New FDA Approval for IBRANCE in Breast Cancer

Pfizer (PFE) announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE (palbociclib) as the first CDK4/6 inhibitor maintenance therapy for adult patients with HR+, HER2+ metastatic breast cancer following induction treatment. This approval opens a new use for the drug in the maintenance setting.

The Product

IBRANCE is a CDK4/6 inhibitor used to treat certain types of breast cancer. The new approval makes it the first approved maintenance therapy after induction treatment for this patient group, potentially improving outcomes and prolonging disease control.

Pricing and Availability

Pfizer has not yet disclosed pricing details for this new indication. It is expected to be available by prescription shortly after approval.

Competition

Pfizer faces competition from other CDK4/6 inhibitors such as Verzenio (Eli Lilly) and Kisqali (Novartis). However, IBRANCE's first-to-market status as a maintenance therapy may provide a competitive edge.

Potential Impact on the Company

The new approval is expected to boost IBRANCE revenues, which is a key oncology drug in Pfizer's portfolio. The full revenue impact will depend on adoption rates in clinical practice.